In focus · trending topic

San Diego Biotechnology Pharm

2 stories · following the connections

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

By Nasdaq OMXApr 4, 2017, 12:00 PM UTC

Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics

By Nasdaq OMXNov 30, 2016, 1:00 PM UTC